2026–2030 Clinical Pipeline & Trial Tracker

Mechanism: Oral deuterated JAK1/JAK2 inhibitor blocking cytokine signaling (IL-15, IFN-gamma) that mediates cytotoxic autoimmune attack on hair follicles.

FDA approved July 2024. Demonstrates outstanding scalp coverage recovery (SALT ≤20) in over 30% of patients with near-total hair loss.

Mechanism: Oral dual-action JAK3 and TEC family kinase inhibitor, selectively blocking cytokine signaling and cytolytic T-cell activity.

First approved therapy for adolescents with severe alopecia areata. Demonstrates durable efficacy with continued dosing.

Mechanism: Oral JAK1/JAK2 inhibitor interrupting intracellular signaling of inflammatory cytokines involved in hair follicle immune privilege collapse.

First FDA-approved systemic therapy for severe alopecia areata (June 2022). Established extensive long-term real-world safety data.

Mechanism: High-affinity competitive androgen receptor antagonist applied topically to the scalp; rapidly metabolised into low-affinity inactive metabolites upon systemic absorption.

Extensively evaluated in Phase 3 registrational trials and Phase 2 combination trials with minoxidil. Strong local antiandrogen candidate without serum DHT drop.

Mechanism: Topical androgen receptor antagonist that competes directly with DHT at the follicular level and hydrolyses rapidly to inert cortexolone in the bloodstream.

Dose-ranging Phase 2 trials demonstrated clear superiority of the 7.5% BID dosage. Phase 3 registrational preparations progressing internationally.

Mechanism: Prostaglandin F2-alpha analogue (bimatoprost) combined with potassium channel opener minoxidil for synergistic anagen prolongation.

First dual-mechanism topical combination seeking formal regulatory approval for AGA.

Mechanism: Topical small molecule Wnt-pathway activator, designed to stimulate dormant follicles.

Extensively studied Wnt activator. Disappointing clinical effect sizes highlight the complexity of isolated Wnt upregulation in human scalp.

Mechanism: Selectively inhibits mitochondrial pyruvate carrier (MPC/PDK), shifting hair follicle stem cells from quiescent oxidative phosphorylation to lactate-producing glycolysis to trigger anagen.

Non-hormonal topical mechanism. Phase 1b demonstrated statistically significant stem cell reactivation and anagen entry in 8 weeks with zero hormonal adverse events.

Mechanism: Topical proteolysis-targeting chimera (PROTAC) that recruits E3 ubiquitin ligase to degrade the androgen receptor protein entirely, rather than merely competing with DHT.

First-in-class degrader. Eliminates the androgen receptor locally on scalp cells with catalytic turnover, minimizing needed dose and bypassing systemic side effects.

Mechanism: Inhibits YAP/TEAD mechanotransduction signalling in surgical wounds, preventing myofibroblast differentiation and promoting regenerative, scarless dermal healing.

Transformative surgical breakthrough: investigator trials show significantly reduced fibrotic scarring in FUE punch sites and partial follicular unit regeneration.

Mechanism: Human monoclonal antibody targeting and blocking prolactin receptor (PRLR) signaling, an alternative pathway inducing follicle regression.

Completely independent of androgen receptors and 5-alpha reductase. Highly promising for female pattern hair loss and non-responders to finasteride.

Mechanism: Sustained-release oral delivery providing continuous follicular sulfotransferase stimulation without the acute Cmax plasma spikes that trigger postural hypotension.

Directly solves the tolerability and safety barrier of immediate-release oral minoxidil while maintaining 24-hour therapeutic follicle exposure.

Mechanism: Blocks prostaglandin D2 receptor signalling, which is elevated in balding scalp and suppresses follicle anagen phase.

Novel non-androgenic mechanism addressing prostaglandin dysregulation in balding tissue.

Mechanism: Controlled micro-wounding triggers an embryonic-like regenerative state; topical HDAC inhibitor amplifies hair follicle neogenesis.

Combines mechanical skin disruption with pharmaceutical epigenetic modulation to trigger de novo follicle formation.

Mechanism: Topical HDAC inhibitor activating the Wnt/beta-catenin signaling cascade in follicular stem cells.

Low-cost repurposed agent showing modest efficacy in East Asian clinical studies.

Mechanism: Patient skin cells reprogrammed into autologous induced pluripotent stem cells (iPSCs), differentiated into dermal papilla cells, and implanted into scalp tissue to de novo form hair follicles.

First-in-human clinical dosing launched. The primary autologous cloning candidate aimed at solving donor depletion permanently.

Mechanism: In-vitro expanded epithelial and mesenchymal dermal papilla cells assembled with proper geometric polarity to generate thousands of functional follicle germs.

Advanced cell-expansion technology operating under Japan's expedited PMDA regenerative medicine regulatory framework.

Mechanism: Exosome nanocarrier delivery of CRISPR base-editors to selectively downregulate AR/SRD5A2 in scalp follicles with no systemic distribution.

High potential curative target. In-vivo rodent data demonstrate permanent localized receptor silencing.